focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSareum Share News (SAR)

Share Price Information for Sareum (SAR)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 38.50
Bid: 38.00
Ask: 39.00
Change: -2.05 (-4.91%)
Spread: 1.00 (2.632%)
Open: 43.50
High: 39.70
Low: 39.70
Prev. Close: 41.75
SAR Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Sareum shares slump on widened loss and funding talks

Tue, 12th Mar 2024 15:23

(Alliance News) - Sareum Holdings PLC share fell on Tuesday, after it said it expects to report a widened interim loss.

Shares in the Cambridge, England-based pharmaceutical company were down 24% to 26.51 pence in London on Tuesday afternoon.

Sareum said it will publish its result the six months ended December 31 in the week beginning March 25.

It expects to report an operating loss of GBP2.5 million, widening from GBP1.7 million a year earlier.

The company explained that this reflects "the cost of continued and additional investment into clinical research conducted during the period for the furtherance of its SDC-1801 autoimmune disease programme."

It also updated markets on its equity prepayment facility with RiverFort Global Opportunities PCC Ltd.

Sareum has drawn GBP2.3 million to date from two prepayment deposits and the company currently has an outstanding balance of approximately GBP1.3 million under the facility.

Any remaining balances are not due for repayment until the maturity date in August 2025, by which all balances are expected to be settled through the issuance of placing shares.

Previously it has been announced that the facility included a committed third tranche prepayment deposit of GBP300,000.

However, it noted that "due to downward pressure on the company's share price", Sareum has been unable to draw down the third prepayment under the facility.

The company explained that it is now in discussions to assess alternative funding arrangements and has taken steps to preserve its immediate capital utilisation.

It added that, providing alternative funding is secured, the board remains confident that it is on course to deliver topline Phase 1a results in the second quarter of 2024.

By Elijah Dale, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.

More News
7 Oct 2021 22:08

TRADING UPDATES: Marlowe buys; Galliford snaps up nmcn's Water unit

TRADING UPDATES: Marlowe buys; Galliford snaps up nmcn's Water unit

Read more
19 Aug 2021 14:25

IN BRIEF: Sareum expects annual loss to widen, increases R&D

IN BRIEF: Sareum expects annual loss to widen, increases R&D

Read more
19 Aug 2021 07:41

Sareum expects FY losses to widen on higher R&D costs, supply delays

(Sharecast News) - British drugmaker Sareum said on Thursday that it expects to post a widened full-year loss as a result of increased research-and-development expenditure and delays in compound supply.

Read more
9 Aug 2021 17:08

TRADING UPDATES: Netcall wins new deal; Sareum raises GBP1 million

TRADING UPDATES: Netcall wins new deal; Sareum raises GBP1 million

Read more
6 Aug 2021 15:00

Sareum positive on SRA737 outlook after Sierra call

(Sharecast News) - Specialist drug development company Sareum noted on Friday that Sierra Oncology, the licence holder for the novel Chk1 inhibitor 'SRA737', had discussed its newly-announced global in-licensing agreement with AstraZeneca for AZD5153 with investors, which is a novel BRD4 BET inhibitor, to expand its myelofibrosis pipeline.

Read more
30 Jul 2021 19:40

TRADING UPDATES: Capita and Custodian REIT agree disposals

TRADING UPDATES: Capita and Custodian REIT agree disposals

Read more
30 Jul 2021 11:00

AIM WINNERS & LOSERS: Sareum in patent boost; Airea flags uncertainty

AIM WINNERS & LOSERS: Sareum in patent boost; Airea flags uncertainty

Read more
19 Jul 2021 19:13

TRADING UPDATES: Sareum raises GBP1 million; Marlowe buys Core Stream

TRADING UPDATES: Sareum raises GBP1 million; Marlowe buys Core Stream

Read more
1 Jul 2021 19:26

TRADING UPDATES: Gym Group bulks up with placing; 88 Energy debt free

TRADING UPDATES: Gym Group bulks up with placing; 88 Energy debt free

Read more
1 Jul 2021 11:18

Sareum releases 'encouraging' results from Covid-19 research

(Sharecast News) - Specialist drug development company Sareum announced "encouraging" top-line results from its UKRI grant-funded Covid-19 research project on Thursday.

Read more
15 Jun 2021 20:28

TRADING UPDATES: Tremor Nasdaq IPO underway; MGC's CannEpil in Ireland

TRADING UPDATES: Tremor Nasdaq IPO underway; MGC's CannEpil in Ireland

Read more
1 Jun 2021 17:43

TRADING UPDATES: Breedon buys Micromix; Marlowe acquires Alarm

TRADING UPDATES: Breedon buys Micromix; Marlowe acquires Alarm

Read more
1 Jun 2021 11:30

AIM WINNERS & LOSERS: Sound Energy falls on Morocco tax notification

AIM WINNERS & LOSERS: Sound Energy falls on Morocco tax notification

Read more
25 May 2021 17:11

TRADING UPDATES: Mothercare sales down; Revolution Bars seeks to raise

TRADING UPDATES: Mothercare sales down; Revolution Bars seeks to raise

Read more
25 May 2021 10:56

Sareum's pre-clinical development of SDC-1801 delayed by Covid-19

(Sharecast News) - Pharmaceutical company Sareum said on Tuesday that Covid-19 has continued to impact the contract research organisations it was working to complete pre-clinical development of its SDC-1801 drug candidate for autoimmune disease.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.